

Table S1. Baseline characteristics, treatment and outcome of patients with end-stage renal disease stratified by concomitant psoriasis (n = 1063) with and without psoriatic arthritis (cumulative data of the years 2005–2020).

Parameters	ESRD and Psoriasis with Psoriatic Arthritis (n = 98; 9.2%)	ESRD and Psoriasis without Psoriatic Arthritis (n = 965; 90.8%)	Absolute Risk Difference (95%CI)
Age (years)	66 (56–75)	66 (56–75)	-
Sex (female)	48 (52.2%)	313 (32.4%)	+16.0% (+6.4%; +26.7%)
Obesity	19 (20.7%)	168 (17.4%)	+1.9% (-5.1%; +11.2%)
In-hospital stay	9 (3–20)	8 (3–16)	-
Comorbidities			
Coronary artery disease	38 (41.3%)	295 (30.6%)	+8.2% (-1.3%; +18.5%)
Malignancy	5 (5.4%)	47 (4.9%)	+0.2% (-3.1%; +6.6%)
Left heart failure	26 (28.3%)	263 (27.3%)	+0.7% (-8.9%; +9.1%)
Right heart failure	11 (11.9%)	103 (10.7%)	+0.5% (-4.7%; +8.5%)
COPD	14 (15.2%)	161 (16.7%)	-2.4% (-8.5%; +6.2%)
Diabetes mellitus	42 (45.6%)	417 (43.2%)	-0.4% (-10.2%; +10.0%)
Arterial hypertension	48 (52.1%)	488 (50.6%)	-1.6% (-11.7%; +8.6%)
Hypertensive Nephropathy	11 (11.9%)	92 (9.5%)	+1.7% (-3.6%; +9.6%)
Atrial fibrillation/-flutter	19 (20.7%)	222 (23.0%)	-3.6% (-10.8%; +5.7%)
Deep vein thrombosis or thrombophlebitis	n. c.	7 (0.7%)	-
Dialysis modalities			
Dialysis general	44 (47.8%)	430 (44.6%)	-0.3% (-9.6%; +10.7%)
Haemofiltration	n. c.	24 (2.5%)	-
Haemodialysis	42 (45.7%)	424 (43.9%)	-1.8% (-10.8%; +5.7%)
Haemodiafiltration	10 (10.9%)	101 (10.5%)	-0.1% (-5.3%; +7.5%)
Adverse events during hospitalization			
Gastro-intestinal bleeding	n. c.	5 (0.0%)	-
Intracranial bleeding	0 (0.0%)	0 (0.0%)	0.0% (-0.0%; +3.8%)
Myocardial infarction	n. c.	12 (1.2%)	-
Ischemic Stroke	0 (0.0%)	11 (1.1%)	-0.1% (-20.3%; +2.7%)
Pulmonary embolism	n. c.	5 (0.5%)	-
Cardio-pulmonary reanimation	n. c.	13 (1.3%)	-
Transfusion of erythrocytes	25 (27.2%)	189 (19.6%)	-5.9% (-2.1%; +15.7%)
MACCE	7 (7.6%)	68 (7.0%)	-0.1% (-3.9%; +7.1%)
In-hospital mortality	6 (6.5%)	53 (5.5%)	-0.6% (-3.1%; +7.4%)

n.c. = not calculable